6
H index
3
i10 index
101
Citations
Paolo Pertile : Citation Profile
Università degli Studi di Verona | RESEARCH PRODUCTION: 21 Articles 19 Papers RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
17 years (2006 - 2023). Relations with other researchers
Works with:
Authors registered in RePEc who have co-authored more than one work in the last five years with Paolo Pertile. | Is cited by:
| Cites to:
|
Main data
Where Paolo Pertile has published?
| Journals with more than one article published | # docs |
|---|---|
| Health Economics | 5 |
| Journal of Health Economics | 3 |
| Journal of Public Economic Theory | 2 |
| Applied Health Economics and Health Policy | 2 |
| Working Papers Series with more than one paper published | # docs |
|---|---|
| Working Papers / University of Verona, Department of Economics | 11 |
| Working Papers / Fondazione Eni Enrico Mattei | 2 |
Recent works citing Paolo Pertile (2024 and 2023)
| Year | Title of citing document |
|---|---|
| 2023 | The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets. (2023). Straume, Odd Rune ; Dalen, Dag Morten ; Brekke, Kurt R. In: Journal of Health Economics. RePEc:eee:jhecon:v:90:y:2023:i:c:s0167629623000553. Full description at Econpapers || Download paper |
| 2023 | The price of cost-effectiveness thresholds. (2023). Straume, Odd Rune ; Dalen, Dag Morten ; Brekke, Kurt R. In: Discussion Paper Series in Economics. RePEc:hhs:nhheco:2023_004. Full description at Econpapers || Download paper |
| 2023 | Value-Based Clinical Trials: Selecting Recruitment Rates and Trial Lengths in Different Regulatory Contexts. (2023). Forster, Martin ; Chick, Stephen E ; Alban, Andres. In: Management Science. RePEc:inm:ormnsc:v:69:y:2023:i:6:p:3516-3535. Full description at Econpapers || Download paper |
Works by Paolo Pertile:
| Year | Title | Type | Cited |
|---|---|---|---|
| 2023 | Dynamic, incentive-compatible contracting for health services In: FEEM Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 2023 | Dynamic, incentive-compatible contracting for health services.(2023) In: Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 0 | paper | |
| 2014 | Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies In: Journal of the Royal Statistical Society Series A. [Full Text][Citation analysis] | article | 7 |
| 2017 | A Bayesian decision theoretic model of sequential experimentation with delayed response In: Journal of the Royal Statistical Society Series B. [Full Text][Citation analysis] | article | 10 |
| 2015 | A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response.(2015) In: Discussion Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 10 | paper | |
| 2008 | Investment in Health Technologies in a Competitive Model with Real Options In: Journal of Public Economic Theory. [Full Text][Citation analysis] | article | 3 |
| 2017 | The Dynamics of Pharmaceutical Regulation and R&D Investments In: Journal of Public Economic Theory. [Full Text][Citation analysis] | article | 5 |
| 2013 | The dynamics of pharmaceutical regulation and R&D investments.(2013) In: Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 5 | paper | |
| 2014 | Two-part payments for the reimbursement of investments in health technologies In: Health Policy. [Full Text][Citation analysis] | article | 8 |
| 2012 | Static and dynamic efficiency of irreversible health care investments under alternative payment rules In: Journal of Health Economics. [Full Text][Citation analysis] | article | 12 |
| 2010 | Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules.(2010) In: Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 12 | paper | |
| 2016 | Late-stage pharmaceutical R&D and pricing policies under two-stage regulation In: Journal of Health Economics. [Full Text][Citation analysis] | article | 7 |
| 2015 | Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation.(2015) In: Discussion Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 7 | paper | |
| 2021 | R&D and market size: Who benefits from orphan drug legislation? In: Journal of Health Economics. [Full Text][Citation analysis] | article | 1 |
| 2017 | A large scale OLG model for the analysis of the redistributive effects of policy reforms In: European Journal of Political Economy. [Full Text][Citation analysis] | article | 16 |
| 2006 | Technology adoption, quality and health care costs: a review of the literature In: STUDI ECONOMICI. [Full Text][Citation analysis] | article | 1 |
| 2009 | The timing of adoption of positron emission tomography: a real options approach In: Health Care Management Science. [Full Text][Citation analysis] | article | 1 |
| 2009 | An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography In: International Journal of Health Economics and Management. [Full Text][Citation analysis] | article | 2 |
| 2015 | The fiscal disadvantage of young Italians: a new view on consolidation and fairness In: The Journal of Economic Inequality. [Full Text][Citation analysis] | article | 1 |
| 2020 | Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 5 |
| 2020 | Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition” In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2016 | Redistribution at the local level: the case of public childcare in Italy In: International Review of Economics. [Full Text][Citation analysis] | article | 4 |
| 2013 | Redistribution at the Local Level: The Case of Public Childcare in Italy.(2013) In: Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 4 | paper | |
| 2011 | Dynamic, economic approaches to HTA under uncertainty In: Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 2012 | Public finance consolidation and fairness across living generations: the case of Italy In: Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 2014 | L’ISEE in Italia: Una Nota Metodologica Partendo dai Dati IT-SILC In: Working Papers. [Full Text][Citation analysis] | paper | 3 |
| 2019 | R&D and market size: who benefits from orphan drug regulation? In: Working Papers. [Full Text][Citation analysis] | paper | 1 |
| 2016 | Pricing policies when patients are heterogeneous: a welfare analysis In: Working Papers. [Full Text][Citation analysis] | paper | 1 |
| 2015 | Who should monitor job sick leave? In: Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 2012 | Modelling life-course decisions for the analysis of interpersonal and intrapersonal redistribution In: Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 2015 | Public policies over the life cycle: a large scale OLG model for France, Italy and Sweden In: Working Papers. [Full Text][Citation analysis] | paper | 1 |
| 2012 | DRGs: the link between investment in technologies and appropriateness In: Working Papers. [Full Text][Citation analysis] | paper | 1 |
| 2013 | Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective In: Health Economics. [Full Text][Citation analysis] | article | 4 |
| 2019 | Job sick leave: Detecting opportunistic behavior In: Health Economics. [Full Text][Citation analysis] | article | 0 |
| 2020 | Which valued?based price when patients are heterogeneous? In: Health Economics. [Full Text][Citation analysis] | article | 2 |
| 2020 | The impact of managed entry agreements on pharmaceutical prices In: Health Economics. [Full Text][Citation analysis] | article | 2 |
| 2021 | A reply to “Who would benefit from average value?based pricing?” In: Health Economics. [Full Text][Citation analysis] | article | 0 |
| 2022 | Spillovers of Pharmaceutical Price Regulations: evidence from the AMNOG Reform in Germany In: Health, Econometrics and Data Group (HEDG) Working Papers. [Full Text][Citation analysis] | paper | 0 |
| 2010 | Optimal sequential sampling rules for the economic evaluation of health technologies In: Discussion Papers. [Full Text][Citation analysis] | paper | 2 |
| 2018 | Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence In: Discussion Papers. [Full Text][Citation analysis] | paper | 1 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated December, 10 2023. Contact: CitEc Team